Liver organoids: established tools for disease modeling and drug development
Open accessThe DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.
Abstract
In the past decade, liver organoids have evolved rapidly as valuable research tools, providing novel insights into almost all types of liver diseases, including monogenic liver diseases, alcohol-associated liver disease, metabolic-associated fatty liver disease, various types of (viral) hepatitis, and liver cancers. Liver organoids in part mimic the microphysiology of the human liver and fill a gap in high-fidelity liver disease models to a certain extent. They hold great promise to elucidate the pathogenic mechanism of a diversity of liver diseases and play a crucial role in drug development. Moreover, it is challenging but opportunistic to apply liver organoids for tailored therapies of various liver diseases. The establishment, applications, and challenges of different types of liver organoids, for example, derived from embryonic, adult, or induced pluripotent stem cells, to model different liver diseases, are presented in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Human liver tissue-derived organoids can be easily expanded in vitro, are bipotent, and differentiate into hepatocytes and/or cholangiocytes. In addition, these organoids show high genomic stability [24, 30] therefore, they have specific advantages over the use of primary or iPSC-derived liver cells.”
From High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. (2026) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“MAFLD, a disease associated with excess lipid accumulation in the liver [30, 31].”
From High-throughput human microfluidic organoid-on-a-chip platform for modeling liver diseases and screening nanotherapeutics. (2026) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Burden of liver diseases in the world
Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.014 · Cited by 3,783
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
A functional CFTR assay using primary cystic fibrosis intestinal organoids
Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999
Cited by
Advancements in Organoid‐Based Drug Discovery: Revolutionizing Precision Medicine and Pharmacology
Singh, D., Thakur, A., Rakesh, & Kumar, A. A. (2025) · Drug Development Research · doi:10.1002/ddr.70121 · Cited by 30
Roy, S., Parveen, M., Bala, A., & Sur, D. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00661 · Cited by 26
Liu, H., Yin, G., Franco Leonardi, B., Lan, T., Ait Ahmed, Y., Berger, H., Kohlhepp, M. S., Amiridze, N., Martagón Calderón, N., Frau, C., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334425 · Cited by 23
“To further elucidate crosstalk pathways in this complex cellular niche, we investigated the influence of ORM2-activated LMFs on HSCs and hepatocytes. mLMF-ORM2 CM significantly enhanced the gene expression levels of Col1a1 , Tgfb1 and Pdgfrb but not Acta2 in HSCs (figure 10A).”
Ariño, S., Ferrer‐Lorente, R., Serrano, G., Zanatto, L., de la Torre, R. A. M. G., Gratacós‐Ginès, J., Rubio, A. B., Pérez-Guasch, M., Mateos-Sánchez, C., Aguilar‐Bravo, B., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.07.014 · Cited by 25
Model Organoids: Integrated Frameworks for the Next Frontier of Healthcare Advancements
Bhattacharya, R., Bose, D., Kaur, T., Patel, R., Renuka, O., & Rodriguez, R. V. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10814-3 · Cited by 19
Metadata
- Authors
- Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K.
- Affiliations
- Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- Shanghai Jiao Tong University (CN)
- University Medical Center Groningen (NL)
- Corresponding author
- Faber, Klaas Nico
- Xia, Qiang
- He, Kang
- Venue
- Hepatology Communications
- Published
- 2023-03-24
- Volume
- 7
- Issue
- 4
- ISSN
- 2471-254X (ISSN-L)
- PMC
- PMC10043560
- OpenAlex
- W4360993648
- Cited by
- 37
- References
- 114
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 8 · 2023: 4
- FWCI
- 1.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Hepatology Communications (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc-nd)
- Funders
- Shanghai Municipal Health Commission
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- liver organoids, liver disease modeling, drug development, alcoholic liver disease, metabolic-associated fatty liver disease, viral hepatitis, liver cancer, induced pluripotent stem cells, embryonic stem cells, adult stem cells, personalized treatment
- MeSH terms
- Drug Development, Adult, Humans, Liver Neoplasms, Organoids, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver organoids: established tools for disease modeling and drug development. https://app.cochat.ai/papers/10.1097/hc9.0000000000000105
- The paper
- Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023). Liver organoids: established tools for disease modeling and drug development. Hepatology Communications. https://doi.org/10.1097/hc9.0000000000000105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.